![]() |
Name |
3-Butanoyl-1,8-dihydroxy-2-methylphenanthrene-9,10-dione
|
Molecular Formula | C19H16O5 | |
IUPAC Name* |
3-butanoyl-1,8-dihydroxy-2-methylphenanthrene-9,10-dione
|
|
SMILES |
CCCC(=O)C1=C(C(=C2C(=C1)C3=C(C(=CC=C3)O)C(=O)C2=O)O)C
|
|
InChI |
InChI=1S/C19H16O5/c1-3-5-13(20)11-8-12-10-6-4-7-14(21)15(10)18(23)19(24)16(12)17(22)9(11)2/h4,6-8,21-22H,3,5H2,1-2H3
|
|
InChIKey |
YJQYHFMKGAVKDP-UHFFFAOYSA-N
|
|
Synonyms |
Murayaquinone; Sch-68631; 3-Butanoyl-1,8-dihydroxy-2-methylphenanthrene-9,10-dione; 100843-91-2; CHEMBL179197; Sch68631; SCHEMBL16010694; DTXSID501043648; BDBM50158807; PKF118-744; SF-2418; Q43871312; 3-butanoyl-1,8-dihydroxy-2-methyl-phenanthrene-9,10-dione; 3-Butyryl-1,8-dihydroxy-2-methyl-phenanthrene-9,10-dione; 3-butyryl-1,8-dihydroxy-2-methylphenanthrene-9,10-dione
|
|
CAS | 100843-91-2 | |
PubChem CID | 482190 | |
ChEMBL ID | CHEMBL179197 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 324.3 | ALogp: | 3.9 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 91.7 | Aromatic Rings: | 3 |
Heavy Atoms: | 24 | QED Weighted: | 0.653 |
Caco-2 Permeability: | -5.135 | MDCK Permeability: | 0.00001030 |
Pgp-inhibitor: | 0.004 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.095 | 20% Bioavailability (F20%): | 0.019 |
30% Bioavailability (F30%): | 0.975 |
Blood-Brain-Barrier Penetration (BBB): | 0.004 | Plasma Protein Binding (PPB): | 97.92% |
Volume Distribution (VD): | 0.423 | Fu: | 5.17% |
CYP1A2-inhibitor: | 0.941 | CYP1A2-substrate: | 0.608 |
CYP2C19-inhibitor: | 0.117 | CYP2C19-substrate: | 0.063 |
CYP2C9-inhibitor: | 0.692 | CYP2C9-substrate: | 0.631 |
CYP2D6-inhibitor: | 0.549 | CYP2D6-substrate: | 0.269 |
CYP3A4-inhibitor: | 0.139 | CYP3A4-substrate: | 0.091 |
Clearance (CL): | 5.291 | Half-life (T1/2): | 0.755 |
hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.24 |
Drug-inuced Liver Injury (DILI): | 0.937 | AMES Toxicity: | 0.765 |
Rat Oral Acute Toxicity: | 0.359 | Maximum Recommended Daily Dose: | 0.936 |
Skin Sensitization: | 0.951 | Carcinogencity: | 0.731 |
Eye Corrosion: | 0.01 | Eye Irritation: | 0.947 |
Respiratory Toxicity: | 0.764 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005572 | ![]() |
0.568 | D0N1FS | ![]() |
0.340 | ||
ENC004413 | ![]() |
0.561 | D0H1AR | ![]() |
0.319 | ||
ENC005573 | ![]() |
0.516 | D01XDL | ![]() |
0.304 | ||
ENC000337 | ![]() |
0.500 | D07VLY | ![]() |
0.286 | ||
ENC004888 | ![]() |
0.438 | D0H2ZW | ![]() |
0.286 | ||
ENC000571 | ![]() |
0.438 | D0C9XJ | ![]() |
0.286 | ||
ENC000087 | ![]() |
0.438 | D08NQZ | ![]() |
0.284 | ||
ENC005571 | ![]() |
0.436 | D0S0LZ | ![]() |
0.284 | ||
ENC005279 | ![]() |
0.435 | D01XWG | ![]() |
0.282 | ||
ENC005280 | ![]() |
0.421 | D0J2NK | ![]() |
0.280 |